Top-News

Die Wachstumsgeschichte: Analysten sehen kurzfristige +37 %-Chance bei diesem europäischen Marktführer(Anzeige)

Adaptimmune Therapeutics Plc. ADR News

Aktie

WKN: A14SUX ISIN: US00653A1079 US-Symbol: ADAP

1,01 €

-0,01 €

-0,98%

20.05.24 16:26:24

Handeln Depot/Watchlist

Aktienanzahl *

227,12 Mio.

Marktkapitalisierung *

230,07 Mio. €

Streubesitz

-

Faktor

6

Originalaktie

Index-Zugehörigkeit

-

IR-Website

*Stand: 03.01.2024

Ad-hocs

22.03.17 - GlobeNewswire

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares PHILADELPHIA and OXFORD, United Kingdom, March 22, 2017 (GLOBE NEWSWIRE) -- ...

28.07.16 - GlobeNewswire

Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma

Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma New ...

26.07.16 - GlobeNewswire

Adaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma

Adaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma PHILADELPHIA and ...

Newssuche

Videos

17.05.24 -2,19%

Technical Trading: Gold Long-Chance

Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »

Die Wachstumsgeschichte

Analysten sehen kurzfristige +37 %-Chance bei diesem europäischen Marktführer
weiterlesen»

Anzeige